Neuropeptide immunocorrection in patients with multiple sclerosis
M. A. Artykova, S. A. Beknazarov · 2025 · Scientific and Innovative Therapy. 2025;(2):3–9. Bukhara State Medical Institute; Zenodo deposit 5 June 2025
What does this source report?
After three courses, the authors report upper-limb motor-score gains of 1.4 versus 0.8 points and lower-limb gains of 1.8 versus 0.9, with reported p<0.05. The proportion described as having reduced work capacity fell from 71.7% to 31.1% with adjunct Cortexin, versus 75.5% to 53.1% in controls. These are reported functional signals, not evidence of disease modification.
- Population and setting
- 63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
- Evidence type
- Human comparative study
- Preparation
- Cortexin tissue-derived peptide preparation
- Source language
- Russian; English and Uzbek abstracts
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Small comparison with unclear allocation, baseline comparability, concomitant therapy and assessment timing; no placebo or blinding described.
- Motor scale, variance and statistical methods are insufficiently specified. Percentages lack underlying counts; immune-marker claims have no numerical table.
- No longitudinal MRI lesion, relapse-rate or EDSS progression outcomes are reported. Safety reporting is insufficient; this does not establish an MS treatment or replacement for disease-modifying therapy.
- A same-title 2021 Artykova–Rakhmatov report exists; cohort overlap remains unresolved and is not counted as independent replication.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Open-access journal PDF; Zenodo repository
Review depth: Full article read; motor table visually checked
Related-report group: cortexin-ms-arty-kova-overlap-unresolved. Reports in this group are not assumed to be independent trials.
Source access and review scope
Methods, results, tables and references reviewed. Randomization, blinding and allocation procedures are not described; this is not classified as a randomized trial.
Recorded source-check date: 2026-10-03. This date does not imply a completed systematic review.
Cite and trace this record
Original source: M. A. Artykova, S. A. Beknazarov. Neuropeptide immunocorrection in patients with multiple sclerosis Scientific and Innovative Therapy. 2025;(2):3–9. Bukhara State Medical Institute; Zenodo deposit 5 June 2025 2025.
Molekul research summary: https://molekul.io/research/cortexin-ms-2025. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry